ATE99698T1 - Peptide. - Google Patents

Peptide.

Info

Publication number
ATE99698T1
ATE99698T1 AT86810444T AT86810444T ATE99698T1 AT E99698 T1 ATE99698 T1 AT E99698T1 AT 86810444 T AT86810444 T AT 86810444T AT 86810444 T AT86810444 T AT 86810444T AT E99698 T1 ATE99698 T1 AT E99698T1
Authority
AT
Austria
Prior art keywords
amino acid
acid residue
protecting group
carbon atoms
peptides
Prior art date
Application number
AT86810444T
Other languages
English (en)
Inventor
Kazuharu Ienaga
Kunihiko Hagashiura
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE99698T1 publication Critical patent/ATE99698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT86810444T 1985-10-14 1986-10-08 Peptide. ATE99698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22964885 1985-10-14
EP86810444A EP0221019B1 (de) 1985-10-14 1986-10-08 Peptide

Publications (1)

Publication Number Publication Date
ATE99698T1 true ATE99698T1 (de) 1994-01-15

Family

ID=16895486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86810444T ATE99698T1 (de) 1985-10-14 1986-10-08 Peptide.

Country Status (6)

Country Link
US (1) US5110797A (de)
EP (1) EP0221019B1 (de)
JP (1) JPH0811746B2 (de)
AT (1) ATE99698T1 (de)
DE (1) DE3689508T2 (de)
ES (1) ES2061442T3 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601398A1 (de) * 1986-01-18 1987-07-23 Fresenius Ag Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen
IT1244548B (it) * 1991-02-06 1994-07-15 Poli Ind Chimica Spa Derivati della 5-oxo-l-prolina e loro applicazioni farmaceutiche
IT1249728B (it) * 1991-11-06 1995-03-09 Sigma Tau Ind Farmaceuti Derivati delle prolinammide quali attivatori della memoria e dei processi di apprendimento e composizioni farmaceutiche che li contengono
WO1995006060A1 (en) * 1993-08-24 1995-03-02 Seikagaku Kogyo Kabushiki Kaisha Peptide compound
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US7613659B1 (en) * 1994-11-28 2009-11-03 Yt Acquisition Corporation System and method for processing tokenless biometric electronic transmissions using an electronic rule module clearinghouse
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
EP1090625B1 (de) * 1999-10-05 2004-12-22 Kao Corporation Topische Zusammensetzung für die Haut und deren Anwendung
WO2002028881A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US20020098999A1 (en) * 2000-10-06 2002-07-25 Gallop Mark A. Compounds for sustained release of orally delivered drugs
AU2002239257A1 (en) * 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1412324A4 (de) * 2001-06-11 2004-09-29 Xenoport Inc Aminosäurekonjugate, die anhaltende systemische konzentrationen von gaba-analoga ergeben
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
EP1951665A1 (de) * 2005-11-14 2008-08-06 Dominion Pharmakine S.L. Neue inhibitoren der lfa-1/icam-1-wechselwirkung und anwendungen davon
WO2008126652A1 (ja) * 2007-03-20 2008-10-23 Shiseido Company, Ltd. 皮膚外用組成物
CN101434645B (zh) * 2008-12-24 2013-01-16 中国农业大学 一种合成寡肽及其用途
WO2012047543A1 (en) * 2010-09-27 2012-04-12 E.I. Du Pont De Nemours And Company Method for preparing 2-amino-n-(2,2,2-trifluoroethyl) acetamide
CN103288673B (zh) * 2013-05-28 2015-05-06 广东药学院 一种铂配体及其配合物
WO2014190533A1 (zh) * 2013-05-31 2014-12-04 广东药学院 一种铂配体及其配合物
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程（武汉）有限公司 γ-羟基丁酸的前药及其组合物和用途
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
KR102982616B1 (ko) 2020-06-18 2026-06-26 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487105A (en) * 1966-12-16 1969-12-30 American Home Prod Alpha-aminoacyl-omega-aminocarboxylic acids
PL216291A1 (de) * 1978-06-14 1980-03-24 Byk Gulden Lomberg Chem Fab
US4316892A (en) * 1980-11-03 1982-02-23 G. D. Searle & Co. 2,6-C-Dimethyltyrosine1 -D-amino acid2 -ε-amino caproic and γ aminobutyric acid5 derivatives of methionine enkephalin
CY1406A (en) * 1980-12-18 1988-04-22 Schering Corp Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase
FR2514898A1 (fr) * 1981-10-16 1983-04-22 Armines Procede, capteur et dispositif de detection de traces ou impuretes gazeuses
US4634716A (en) * 1982-09-30 1987-01-06 Merck & Co., Inc. Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents
JPS59159756A (ja) * 1983-03-04 1984-09-10 Ajinomoto Co Inc 鹹味付与剤
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
IT1169420B (it) * 1983-05-24 1987-05-27 Maria Curti Composti dotati di attivita' sedativa e tranquillante,procedimenti per prepararli e composizioni che li contengono
US4599325A (en) * 1984-02-16 1986-07-08 G. D. Searle & Co. Substituted tyrosyl alanine dipeptide amides
EP0225292A3 (de) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Einige N-substituierte Buttersäureamidderivate
US4908353A (en) * 1987-10-16 1990-03-13 Nippon Zoki Pharmaceutical Co., Ltd. Novel dipeptide useful as a plant growth regulator

Also Published As

Publication number Publication date
JPH0811746B2 (ja) 1996-02-07
US5110797A (en) 1992-05-05
DE3689508D1 (de) 1994-02-17
EP0221019B1 (de) 1994-01-05
ES2061442T3 (es) 1994-12-16
EP0221019A3 (en) 1989-12-27
DE3689508T2 (de) 1994-05-11
EP0221019A2 (de) 1987-05-06
JPS62270552A (ja) 1987-11-24

Similar Documents

Publication Publication Date Title
DE3689508D1 (de) Peptide.
DK126389D0 (da) Peptidforbindelser
BR9713366A (pt) Análogos de heptapeptìdeo oxitocina
AU7361091A (en) 1, 4, 7, 10-tetraazacyclodedecane butyltriols, processes for their production and pharmaceutical agents containing them
DE3850550D1 (de) Dipeptide, verwendbar als Pflanzenwachstumsregulatoren.
ZA865696B (en) Peptide amino-alcohol derivatives containing a tetrasubstituted carbon atom,inhibiting renin and acid proteases,process for obtention and therapeutical use
ES8501412A1 (es) "un metodo para la preparacion de un derivado de aminoacido"
GB2217331B (en) Oligopeptides and their use as analgesics
HUT42102A (en) Process for preparing peptides with pharmaceutical activity
RU1804462C (en) Method of cefem compounds or theirs salts synthesis
ATE46347T1 (de) Immunostimulierende peptide.
ATE99322T1 (de) Loesungssynthese eines oktapeptids.
ZA888335B (en) Vincristine-containing product
IL107043A0 (en) Novel pharmaceutically active flavilium compounds
GR852126B (de)
EP0311391A3 (en) New process for preparing an octapeptide
MY111630A (en) Amino acid derivatives.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee